Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116023, China.
Engineering Research Center for New Materials and Precision Treatment Technology of Malignant Tumors Therapy, Dalian Medical University, Dalian, 116044, China.
Proteomics Clin Appl. 2020 Jul;14(4):e1900080. doi: 10.1002/prca.201900080. Epub 2020 Mar 12.
The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure. A deeper understanding of the drug resistance mechanism of tumor cells is very significant for improving the clinical prognosis of patients with HCC.
In this study, proteomic studies on the composition of 5-fluorouracil (5-Fu) resistant Bel/5Fu cell line and its parent Bel7402 cell line by using an ionic liquid assisted proteins extraction method with the advantage of extracting plasma membrane proteins to a wider extent are performed. Then the expression level and function of differentially expressed plasma membrane proteins are verified.
In total, 25 plasma membrane proteins are shown differentially expressed in Bel/5Fu compared with Bel7402. Western blot analysis results further confirmed that the EPHX1 PLIN2 RAB27B SLC4A2 are upregulated in Bel/5Fu cells in accordance with the proteomics data. Moreover, cell viability assay and clonogenic survival assay results demonstrated that EPHX1 is closely related to the chemoresistance of Bel/5Fu to 5-Fu.
Plasma membrane protein EPHX1 is closely related to the chemotherapy resistance of Bel/5Fu cells and can be used as a new drug target to improve the clinical prognosis of patients with HCC.
肝癌(HCC)的广泛耐药性已成为化疗失败的主要原因。深入了解肿瘤细胞的耐药机制对于改善 HCC 患者的临床预后具有重要意义。
本研究采用离子液体辅助蛋白质提取方法,对具有 5-氟尿嘧啶(5-Fu)耐药性的 Bel/5Fu 细胞系及其亲本 Bel7402 细胞系的组成进行蛋白质组学研究,该方法具有更广泛地提取质膜蛋白的优势。然后验证差异表达的质膜蛋白的表达水平和功能。
与 Bel7402 相比,Bel/5Fu 中有 25 种质膜蛋白表达差异。Western blot 分析结果进一步证实,EPHX1、PLIN2、RAB27B 和 SLC4A2 在 Bel/5Fu 细胞中上调,与蛋白质组学数据一致。此外,细胞活力测定和集落形成存活测定结果表明,EPHX1 与 Bel/5Fu 对 5-Fu 的化疗耐药性密切相关。
质膜蛋白 EPHX1 与 Bel/5Fu 细胞的化疗耐药性密切相关,可作为改善 HCC 患者临床预后的新药物靶点。